stockrow
Saturday 7 November 2026
Export PBLA’s income statement to Excel — free account
Panbela Therapeutics Inc.
PBLA Healthcare Biotechnology
0.01
0.01
Infinity
Follow PBLA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM Sep ’24 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 21 | 21 | 21 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | (5) | (11) | (6) | (7) | (5) | (11) | (35) | (25) | (28) | +24.6% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | (5) | 0 | (6) | (6) | (5) | (10) | (35) | (25) | (28) | +25.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (1.60) | (2.91) | (1,519.92) | (26,103.83) | (14,894.89) | (20,900.90) | (40,786.79) | (231.77) | (32.27) | +103.6% | ||||||
| Cash flow | — | — | (0.77) | (38.14) | (612.05) | (11,532.00) | (12,846.67) | (14,490.00) | (19,095.00) | (231.64) | (3.21) | +125.9% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (825.00) | 3.67 | 0.24 | n/m | ||||||
| Free cash flow | — | — | (0.77) | (38.14) | (612.05) | (11,532.00) | (12,846.67) | (14,490.00) | (19,920.00) | (227.97) | (2.97) | +125.4% | ||||||
| Book value | — | — | (1.49) | (41.36) | 68.72 | 5,831.26 | 28,160.00 | 20,424.00 | (10,061.25) | (43.21) | (3.74) | +61.7% | ||||||
| Shares, m | — | — | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | (38.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (3) | (2) | (3) | (4) | (7) | (15) | (25) | (16) | +40.0% | |||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | 1 | n/m | ||||||
| Free cash flow | — | — | (2) | (3) | (2) | (3) | (4) | (7) | (16) | (25) | (14) | +39.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (5) | (3) | 0 | 1 | 8 | 10 | (6) | (9) | (15) | +10.4% | |||||
| Net debt | — | — | 3 | 2 | (1) | (2) | (9) | (12) | 5 | 3 | 4 | (1.2%) | ||||||
| Shareholders’ equity | — | — | (5) | (4) | 0 | 1 | 8 | 10 | (8) | (5) | (18) | +0.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (621.90) | (2,365.79) | (425.59) | (245.93) | (73.60) | (89.35) | (391.41) | (301.11) | (353.47) | +320.8 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 122.72 | 249.05 | 345.22 | (750.15) | (96.98) | (108.63) | (3,230.05) | 396.00 | 270.37 | +273.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 5 | 6 | 6 | 7 | 8 | — | +12.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Panbela Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CVKD Cadrenal Therapeutics, Inc. | $3.6M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $3.5M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $3.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | |
| ONCO Onconetix, Inc. | $3.2M | — (loss-making) | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.1M | — (loss-making) | — (loss-making) | −85.95% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | (2.67%) | 0.00% | Compare |
| Median of peers | $3.4M | — | — | −83.94% | — | −14.12% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 4 April 2024
Ownership
Directors and executive officers, together
less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement